About me
Bookshop

Get new posts by email.

About me

Weekend read: Not all unpublished trials are sinister

Weekend Read

I recently had the pleasure of meeting Sir Simon Wessely – a renowned British psychiatrist. He’s exactly as lovely as he seems in his writing!

On the same day that I met Sir Simon, I had been discussing the challenges of publishing ‘lost’ clinical trials with someone else. I wish I’d discussed it with him, because then I could claim some sort of tangential influence on his decision to write my recommended read for this weekend: a blog post in which he describes a ‘lost’ trial involving him.

It is easy to claim that non-publication of trials may be result of deliberate decisions, such as a wish not to publicise negative results, and we know this does indeed happen. But probably more common is a more understandable and human sequence of events. A first attempt at publication fails. Teams break up. Some leave academic life and start families. Others move into busy clinical posts, or take on new demanding projects. And time marches on.

As you see, it adds a neat anecdotal riposte to the growing clamour of voices which seem to claim – intentionally or otherwise – that non-publication of trials is always a function of ‘evil’ people working for ‘big pharma’. It’s well worth a read.

This post was filed under: Weekend Reads, , .




The content of this site is copyright protected by a Creative Commons License, with some rights reserved. All trademarks, images and logos remain the property of their respective owners. The accuracy of information on this site is in no way guaranteed. Opinions expressed are solely those of the author. No responsibility can be accepted for any loss or damage caused by reliance on the information provided by this site. Information about cookies and the handling of emails submitted for the 'new posts by email' service can be found in the privacy policy. This site uses affiliate links: if you buy something via a link on this site, I might get a small percentage in commission. Here's hoping.